217 related articles for article (PubMed ID: 37799111)
1. Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases.
Dempsey JL; Ioannou GN; Carr RM
Semin Liver Dis; 2023 Nov; 43(4):367-382. PubMed ID: 37799111
[TBL] [Abstract][Full Text] [Related]
2. Lipid Droplet-Associated Proteins Perilipin 1 and 2: Molecular Markers of Steatosis and Microvesicular Steatotic Foci in Chronic Hepatitis C.
Schelbert S; Schindeldecker M; Drebber U; Witzel HR; Weinmann A; Dries V; Schirmacher P; Roth W; Straub BK
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555099
[TBL] [Abstract][Full Text] [Related]
3. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
4. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
5. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
Staufer K; Stauber RE
Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
[TBL] [Abstract][Full Text] [Related]
6. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
[TBL] [Abstract][Full Text] [Related]
7. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
8. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
9. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
Ochoa-Allemant P; Marrero JA; Serper M
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
[TBL] [Abstract][Full Text] [Related]
10. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
[TBL] [Abstract][Full Text] [Related]
11. MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Yardeni D; Shiloh A; Lipnizkiy I; Nevo-Shor A; Abufreha N; Munteanu D; Novack V; Etzion O
Sci Rep; 2023 Dec; 13(1):22113. PubMed ID: 38092876
[TBL] [Abstract][Full Text] [Related]
12. FK-binding protein 5: Possible relevance to the pathogenesis of metabolic dysfunction and alcohol-associated liver disease.
Ma J; Yang Z; Gao H; Huda N; Jiang Y; Liangpunsakul S
J Investig Med; 2024 Jan; 72(1):128-138. PubMed ID: 37807186
[TBL] [Abstract][Full Text] [Related]
13. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
Jiang Y; Wu L; Zhu X; Bian H; Gao X; Xia M
Lipids Health Dis; 2024 Apr; 23(1):95. PubMed ID: 38566209
[TBL] [Abstract][Full Text] [Related]
14. Lipid droplets in steatotic liver disease.
Bilson J; Scorletti E
Curr Opin Clin Nutr Metab Care; 2024 Mar; 27(2):91-97. PubMed ID: 38320158
[TBL] [Abstract][Full Text] [Related]
15. Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD.
Kim SJ; Hyun J
Mol Cells; 2024 Feb; 47(2):100010. PubMed ID: 38237744
[TBL] [Abstract][Full Text] [Related]
16. Hepatic lipid droplet homeostasis and fatty liver disease.
Seebacher F; Zeigerer A; Kory N; Krahmer N
Semin Cell Dev Biol; 2020 Dec; 108():72-81. PubMed ID: 32444289
[TBL] [Abstract][Full Text] [Related]
17. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
18. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease.
Sawada K; Chung H; Softic S; Moreno-Fernandez ME; Divanovic S
Cell Metab; 2023 Nov; 35(11):1852-1871. PubMed ID: 37939656
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Hansen CD; Lindvig KP; Grønbæk H; Gluud LL; Thiele M; Krag A
Ugeskr Laeger; 2024 May; 186(19):. PubMed ID: 38808766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
